Skip to main content
Premium Trial:

Request an Annual Quote

Ezose Wins Michael J Fox Foundation Grant for Work on Glycans Linked to Parkinson's

Premium

Ezose Sciences said this week that it has received a grant from the Michael J Fox Foundation for Parkinson's Research to investigate the role of glycans in Parkinson's disease.

The company will use its GlycanMap technology to compare glycan profiles and their changes over time in brain stem tissue from rat models of the disease and controls.

“Two important steps toward the development of a disease-modifying therapy for Parkinson’s are greater understanding of the underlying pathology of the disease and validation of a reliable biomarker. Ezose’s glycan analysis offers a new approach to serve those goals and bring us closer to a Parkinson’s cure,” Mark Frasier, vice president of research programs at the Michael J Fox Foundation, said in a statement.

The GlycanMap platform uses an automated 96-well format, high-throughput glycan enrichment system linked to MALDI-TOF mass spec to enable quantitative analysis of the molecules with the aim of discovering glycan changes linked to altered protein function.

The amount of the grant was not disclosed.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.